Trials / Conditions / Partial Onset Seizures

Partial Onset Seizures

26 registered clinical trials studyying Partial Onset Seizures — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Gen NCT06657378	Eisai Co., Ltd.	—
Completed	A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Pa NCT04252846	Eisai Limited	—
Recruiting	A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Parti NCT04015141	Eisai Inc.	Phase 2
Completed	A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Parti NCT03836924	Eisai Pharmaceuticals India Pvt. Ltd	—
Completed	Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects NCT03288129	Eisai Inc.	Phase 4
Completed	Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partia NCT03201900	Eisai Co., Ltd.	Phase 3
Completed	A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With Ep NCT04230044	Eisai Co., Ltd.	—
Completed	Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy NCT02736162	Eisai Inc.	—
Completed	A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of NCT02072824	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 3
Completed	Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onse NCT02192814	UCB Japan Co. Ltd.	Phase 3
Completed	A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Pa NCT02124564	UCB Japan Co. Ltd.	Phase 3
Completed	Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Ad NCT01832038	UCB Pharma SA	Phase 3
Completed	A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset NCT01710657	UCB Pharma SA	Phase 3
Completed	A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administe NCT01618695	Eisai Co., Ltd.	Phase 3
Completed	A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizu NCT01830400	Eisai Inc.	—
Completed	A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patie NCT01830868	Eisai Inc.	—
Completed	An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy NCT01506882	UCB Japan Co. Ltd.	Phase 3
Completed	An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures NCT01407523	UCB Japan Co. Ltd.	Phase 2
Completed	Phase II BGG492 Capsule Extension for Partial Epilepsy NCT01338805	Novartis Pharmaceuticals	Phase 2
Withdrawn	Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures NCT01167335	Novartis	Phase 2
Completed	Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures NCT01147003	Novartis	Phase 2
Completed	Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial O NCT01051193	Nobelpharma	Phase 2 / Phase 3
Completed	Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial O NCT00975715	Novartis Pharmaceuticals	Phase 2 / Phase 3
Completed	Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset S NCT00655551	UCB BIOSCIENCES, Inc.	Phase 3
Completed	Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures NCT00655486	UCB BIOSCIENCES, Inc.	Phase 3
No Longer Available	An Extended Access Program for Perampanel NCT01871233	Eisai Inc.	—